JP2023533003A5 - - Google Patents

Info

Publication number
JP2023533003A5
JP2023533003A5 JP2023500425A JP2023500425A JP2023533003A5 JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5 JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023500425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533003A (ja
JP7712703B2 (ja
Filing date
Publication date
Priority claimed from CN202010633550.2A external-priority patent/CN113896711A/zh
Application filed filed Critical
Publication of JP2023533003A publication Critical patent/JP2023533003A/ja
Publication of JP2023533003A5 publication Critical patent/JP2023533003A5/ja
Application granted granted Critical
Publication of JP7712703B2 publication Critical patent/JP7712703B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023500425A 2020-07-06 2021-06-28 ヘテロ環式免疫調節物質 Active JP7712703B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010633550.2 2020-07-06
CN202010633550.2A CN113896711A (zh) 2020-07-06 2020-07-06 杂环类免疫调节剂
PCT/CN2021/102873 WO2022007659A1 (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂

Publications (3)

Publication Number Publication Date
JP2023533003A JP2023533003A (ja) 2023-08-01
JP2023533003A5 true JP2023533003A5 (cg-RX-API-DMAC7.html) 2024-05-14
JP7712703B2 JP7712703B2 (ja) 2025-07-24

Family

ID=79186707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500425A Active JP7712703B2 (ja) 2020-07-06 2021-06-28 ヘテロ環式免疫調節物質

Country Status (9)

Country Link
US (1) US20230271933A1 (cg-RX-API-DMAC7.html)
EP (1) EP4177247A4 (cg-RX-API-DMAC7.html)
JP (1) JP7712703B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230037035A (cg-RX-API-DMAC7.html)
CN (2) CN113896711A (cg-RX-API-DMAC7.html)
AU (1) AU2021303635A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189041A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000382A (cg-RX-API-DMAC7.html)
WO (1) WO2022007659A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522795A (ja) * 2022-06-27 2025-07-17 ピン セラピューティクス、インコーポレイテッド カゼインキナーゼ1アルファを分解するための化合物及び方法
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
EP4644382A4 (en) * 2022-12-27 2026-04-01 Gluetacs Therapeutics Shanghai Co Ltd ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE
WO2024222614A1 (zh) * 2023-04-28 2024-10-31 北京诺诚健华医药科技有限公司 杂环类gspt1降解剂
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1211577A1 (en) 2012-08-09 2016-05-27 细胞基因公司 Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CA3000547C (en) * 2015-09-29 2021-03-23 Kangpu Biopharmaceuticals, Ltd. Pharmaceutical composition comprising benzoheterocyclic compound and androgen receptor pathway modulator for prevention or treatment of prostate cancer
SI3526202T1 (sl) * 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
JP7062010B2 (ja) * 2017-01-27 2022-05-02 セルジーン コーポレイション 3-(1-オキソ-4-((4-((3-オキソモルホリノ)メチル)ベンジル)オキシ)イソインドリン-2-イル)ピペリジン-2,6-ジオン及びそのアイソトポログ
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
CN107739389B (zh) 2017-11-03 2020-03-31 华东师范大学 3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法
IL278854B2 (en) * 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
WO2020023782A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제

Similar Documents

Publication Publication Date Title
JP2025510656A5 (cg-RX-API-DMAC7.html)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
JP2020521740A5 (cg-RX-API-DMAC7.html)
US20230312528A1 (en) 2-oxo-imidazolidine-4-carboxamides as nav1.8 inhibitors
JP2020526534A5 (cg-RX-API-DMAC7.html)
JP2014513110A5 (cg-RX-API-DMAC7.html)
JP2020519606A5 (cg-RX-API-DMAC7.html)
JP2017528487A5 (cg-RX-API-DMAC7.html)
JP2005534669A5 (cg-RX-API-DMAC7.html)
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2022553376A5 (cg-RX-API-DMAC7.html)
JP2015533177A5 (cg-RX-API-DMAC7.html)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2020506895A5 (cg-RX-API-DMAC7.html)
JP2008509949A5 (cg-RX-API-DMAC7.html)
JP2013545808A5 (cg-RX-API-DMAC7.html)
JP2023531709A5 (cg-RX-API-DMAC7.html)
JP2025503448A5 (cg-RX-API-DMAC7.html)
JP2022529309A5 (cg-RX-API-DMAC7.html)
JP2020520925A5 (cg-RX-API-DMAC7.html)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
JP2023531495A5 (cg-RX-API-DMAC7.html)
JP2023552838A5 (cg-RX-API-DMAC7.html)